What Gino-Daktanol Treats: Main Uses and Benefits

Gino-Daktanol (Miconazole Nitrate) is indicated for the management and symptomatic relief of Vulvovaginal Candidiasis (VVC), an infection caused by Candida fungal overgrowth. This local treatment is utilized in clinical situations characterized by specific symptoms where targeted anti-infective support is appropriate.

This medication is primarily used to address the underlying infectious cause—Vulvovaginal Candidiasis—and is also relevant for managing associated localized discomfort. The therapeutic application is relevant for addressing the fungal infection itself and for easing symptom clusters that may become intense or disruptive, such as pruritus (itching), burning, and physical manifestations like redness, swelling, and abnormal vaginal discharge. The elimination of fungal pathogens assists with managing the condition and helps with the easing of symptomatic manifestations, which contributes to reducing the overall symptom load.

The medication is commonly used for conditions presenting with acute episodes. It helps manage pronounced sensory symptoms, offering symptomatic relief during these episodes.

The local administration of Miconazole is a primary approach to managing the immediate symptoms and cause of uncomplicated vaginal yeast infections.

---

Quick Fact: Provides symptomatic relief during difficult episodes by easing the discomfort of Vulvovaginal Pruritus.

---

Regulatory References

1. DailyMed (U.S. National Library of Medicine) drug label for Miconazole Nitrate

Who can and cannot use Gino-Daktanol? — Official Regulatory Information

This medicine is a local antifungal agent (miconazole nitrate) intended for intravaginal use. Eligibility for use is determined by specific regulatory criteria, primarily related to patient status, age, and underlying health conditions.

Eligibility Classification	Population / Condition
Contraindicated	Individuals with known hypersensitivity to miconazole/miconazole nitrate, other imidazole derivatives, or any component of the formulation.
Restricted / Caution	Patients taking oral anticoagulants (e.g., warfarin) due to the potential for interaction; use requires monitoring.
Not Recommended	Concomitant use with latex contraceptives (condoms, diaphragms) as the medication may impair their effectiveness.
Use Requires Physician Advice	Children under 12 years of age.
Use Requires Physician Advice	Women with first-time vaginal symptoms; recurrence within two months; or symptoms accompanied by fever, chills, abdominal pain, or foul-smelling discharge.
Use Requires Caution/Essential Only	First trimester of pregnancy (use only if essential to patient welfare). Lactation (breastfeeding) due to unknown excretion in human milk.
Considered Eligible	Adults and adolescents ge 12 years of age. Pregnant women (generally after the first trimester).

Eligibility to use Gino-Daktanol is strictly defined by regulatory documents, prohibiting its use in cases of documented allergy to the active substance or its class. Furthermore, the official labeling mandates physician consultation for pediatric patients, for women experiencing their initial infection, and for those with complex or systemic symptoms. The official profile also places restrictions and cautions on use during early pregnancy, lactation, and when certain concomitant medications, such as warfarin, or latex contraceptive methods are used.

Gino-Daktanol (Miconazole Nitrate) has officially documented interaction patterns stemming from its potential for enzyme inhibition and specific local incompatibilities. The medicinal product categories with documented interactions include Coumarin Anticoagulants and specific substrates of the CYP2C9 and CYP3A4 metabolic enzymes, such as Oral Hypoglycemics and Phenytoin.

The most critical regulatory concern involves Warfarin and other Coumarin anticoagulants, where Miconazole's metabolic inhibition leads to a pharmacodynamic potentiation. This process enhances the anticoagulant effect and carries an officially recognized risk of bleeding, classifying it as a clinically significant interaction that requires careful monitoring.

A mandatory interaction-related restriction applies to physical products: the excipients in the vaginal formulation can chemically damage the material of latex or rubber condoms and diaphragms, resulting in the official failure of the barrier contraceptive method. Concurrent use is also restricted with other vaginal products, including tampons, douches, and spermicides, to prevent physical interference or reduced efficacy. Regulatory documents also note the potential for increased systemic exposure of certain hormonal components used in contraceptive rings.

Gino-Daktanol contains miconazole, an imidazole-class agent. Its primary biological target is the fungal cytochrome P450 enzyme, 14alpha-lanosterol demethylase ( CYP51). Miconazole acts as an inhibitor of this enzyme, blocking the conversion of lanosterol into ergosterol.

Ergosterol is an essential sterol for maintaining the structural integrity and functional properties of the fungal cell membrane, analogous to cholesterol in mammalian cells. The inhibition of CYP51 causes an intracellular accumulation of 14alpha-methylsterols (e.g., lanosterol) and a depletion of the critical ergosterol component.

This altered molecular and intracellular sterol composition leads to a direct loss of cell membrane permeability and increased membrane rigidity. Downstream cascades include the leakage of intracellular components such as potassium ions, phosphates, and nucleic acids. Additionally, miconazole directly interacts with membrane phospholipids and induces the intracellular production of Reactive Oxygen Species ( ROS). The system-level physiological consequence is the disruption of fungal cellular structure, resulting in irreversible cellular damage and loss of reproductive capability.

How to use Gino-Daktanol

The usage of Gino-Daktanol, which contains Miconazole Nitrate, follows fixed-course instructions. This section describes the administration methods and schedules for the medicine.

Administration Routes and Forms

Administration Route	Dosage Forms
Intravaginal	Vaginal Suppository; Vaginal Cream
Topical	External Cream (Vulvar/Perianal use)

Labeled Dosing Regimens and Schedule

The standard adult dosing (for those 12 years and over) is based on the product strength and requires completion of the specified course, typically administered once daily at bedtime for internal application.

Treatment Duration	Standard Dose and Form
1-Day Therapy	1200 mg Vaginal Suppository
3-Day Therapy	200 mg Suppository OR 4% Vaginal Cream
7-Day Therapy	100 mg Suppository OR 2% Vaginal Cream

Key Procedural Instructions

Standard administration involves adherence to the full treatment duration, which is not interrupted by menstruation. The intravaginal dose is inserted as high as possible, and the applicator is cleaned after use, if reusable. During the course of treatment, standard use involves avoiding tampons, douches, spermicides, or other vaginal products as these may interfere with the intended localized action of the medicine.

Evidence for Treatment of Vulvovaginal Candidiasis (VVC)

Research has primarily studied Gino-Daktanol in the setting of conditions characterized by fluctuating or episodic manifestations, specifically vaginal yeast infections (VVC). Studies have been applied in research contexts involving fluctuating or unstable symptoms to monitor how they change over defined time intervals. Research generally monitored patterns related to the short-term use of the product.

The findings describe patterns observed in the studies where participants was studied for short-term symptom relief. However, the certainty remains low for predicting whether an individual will experience a similar pattern. It is important to understand that the results apply only to the populations studied, and the follow-up durations were limited. Evidence is limited regarding the complete prevention of recurrence. These studies help show what has been observed so far in specific research settings.

---

Evidence for Treatment of Secondary Bacterial Infections

Research has also was evaluated in studies that research examined its use in cases where a fungal infection is accompanied by certain types of bacterial imbalance. The research explored whether using Gino-Daktanol may be associated with changes in the overall vaginal environment. Current data show patterns related to changes in outcomes linked to inflammatory or irritative states.

Comparative evidence is lacking for Gino-Daktanol when contrasted with treatments specifically targeting only the bacteria. The data are still emerging in this area, meaning research is ongoing to clarify the use of the product’s antifungal component in these mixed conditions associated with acute or disruptive episodes.

---

Evidence in Special Populations

Research has specifically explored how Gino-Daktanol was studied for use in certain populations, such as in patients with comorbid conditions or those at the extremes of age. For pregnant and breastfeeding populations, research has evaluated it in limited settings. The available evidence is limited for these groups, and data for certain groups remain insufficient. Certainty remains low regarding broad conclusions for all individuals in these stages of life. The evidence highlights what is known — and what is still uncertain — about the use of the product.

How to Store and Dispose of Gino-Daktanol

Storage and disposal requirements for Gino-Daktanol (Miconazole Nitrate Vaginal Suppositories/Cream) are defined by official regulatory documentation to ensure product stability and patient safety.

Storage Conditions

The product must be stored at Controlled Room Temperature, specifically between 15°C and 30°C (59°F and 86°F). It is mandatory to keep the medicine from freezing and to store it away from excess heat and moisture. The product must be kept in the original container with the lid tightly closed.

Safety and Disposal

All medicines, including Miconazole, must be stored out of the reach of children. For disposal, throw away any unused or expired product according to official guidelines, such as following FDA disposal procedures. The preferred method is often a medication take-back program.